Aspira Women's Health Files Q2 2025 10-Q
Ticker: AWHL · Form: 10-Q · Filed: 2025-08-13T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, healthcare
TL;DR
Aspira Women's Health filed its Q2 2025 10-Q. Check financials.
AI Summary
Aspira Women's Health Inc. filed its 10-Q for the period ending June 30, 2025. The filing details financial performance and operational updates for the second quarter. Key financial data and business developments are presented, reflecting the company's ongoing activities in the women's health sector.
Why It Matters
This filing provides investors and stakeholders with the latest financial and operational performance of Aspira Women's Health Inc., crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — 10-Q filings are standard for public companies, but the specific financial health and market position of Aspira Women's Health Inc. would determine the actual risk.
Key Numbers
- Q2 2025 — Reporting Period (Second quarter of 2025 financial performance)
- 20250630 — Period End Date (The end date for the financial reporting period)
- 20250813 — Filing Date (The date the 10-Q was officially submitted to the SEC)
Key Players & Entities
- Aspira Women's Health Inc. (company) — Filer of the 10-Q
- 20250630 (date) — End of reporting period
- 20250813 (date) — Filing date
- VERMILLION, INC. (company) — Former company name
- CIPHERGEN BIOSYSTEMS INC (company) — Former company name
- ABIOTIC SYSTEMS (company) — Former company name
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is for the quarter ended June 30, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on August 13, 2025.
What is the company's primary business classification?
The company is classified under 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' with SIC code 2835.
What were the previous names of Aspira Women's Health Inc.?
Previous names include VERMILLION, INC., CIPHERGEN BIOSYSTEMS INC, and ABIOTIC SYSTEMS.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
From the Filing
0001493152-25-011865.txt : 20250813 0001493152-25-011865.hdr.sgml : 20250813 20250812181209 ACCESSION NUMBER: 0001493152-25-011865 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250813 DATE AS OF CHANGE: 20250812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences EIN: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 251208335 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 10-Q 1 form10-q.htm 10-Q false --12-31 Q2 0000926617 0000926617 2025-01-01 2025-06-30 0000926617 2025-08-08 0000926617 2025-06-30 0000926617 2024-12-31 0000926617 2025-04-01 2025-06-30 0000926617 2024-04-01 2024-06-30 0000926617 2024-01-01 2024-06-30 0000926617 us-gaap:ProductMember 2025-04-01 2025-06-30 0000926617 us-gaap:ProductMember 2024-04-01 2024-06-30 0000926617 us-gaap:ProductMember 2025-01-01 2025-06-30 0000926617 us-gaap:ProductMember 2024-01-01 2024-06-30 0000926617 us-gaap:CommonStockMember 2024-12-31 0000926617 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000926617 us-gaap:RetainedEarningsMember 2024-12-31 0000926617 us-gaap:CommonStockMember 2025-03-31 0000926617 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000926617 us-gaap:RetainedEarningsMember 2025-03-31 0000926617 2025-03-31 0000926617 us-gaap:CommonStockMember 2023-12-31 0000926617 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000926617 us-gaap:RetainedEarningsMember 2023-12-31 0000926617 2023-12-31 0000926617 us-gaap:CommonStockMember 2024-03-31 0000926617 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000926617 us-gaap:RetainedEarningsMember 2024-03-31 0000926617 2024-03-31 0000926617 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000926617 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000926617 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000926617 2025-01-01 2025-03-31 0000926617 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000926617 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000926617 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000926617 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000926617 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000926617 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000926617 2024-01-01 2024-03-31 0000926617 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000926617 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000926617 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000926617 us-gaap:CommonStockMember 2025-06-30 0000926617 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000926617 us-gaap:RetainedEarningsMember 2025-06-30 0000926617 us-gaap:CommonStockMember 2024-06-30 0000926617 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000926617 us-gaap:RetainedEarningsMember 2024-06-30 0000926617 2024-06-30 0000926617 AWHL:EquityLineOfCreditAgreementMember 2025-01-01 2025-06-30 0000926617 AWHL:EquityLineOfCreditAgreementMember 2024-01-01 2024-06-30 0000926617 AWHL:TwoThousandTwentyFourDirectOfferingMember 2025-01-01 2025-06-30 0000926617 AWHL:TwoThousandTwentyFourDirectOfferingMember 2024-01-01 2024-06-30 0000926617 AWHL:TwoThousandTwentyFourAtTheMarketOfferingAgreementMember 2025-01-01 2025-06-30 0000926617 AWHL:TwoThousandTwentyFourAtTheM